Name: DENALI THERAPEUTICS INC (DNLI) Stock
Brand: DENALI THERAPEUTICS INC
Rating: 6 (3 reviews)

DNLI Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: The Motley Fool - Mentions: PLAB AVAV GEV

Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More

4 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

4 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

5 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

5 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

9 days ago - By: Zacks Investment Research - Mentions: BIIB RPRX TAK

Denali Enters Into a $275M Funding Deal With Royalty Pharma

10 days ago - By: Royalty Pharma plc - Mentions: RPRX

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

10 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

10 days ago - By: Denali Therapeutics Inc. - Mentions: RPRX

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

a month ago - By: Zacks Investment Research - Mentions: BIIB ALKS TAK

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

a month ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

a month ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

a month ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Board and Executive Leadership Updates

a month ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Board and Executive Leadership Updates

2 months ago - By: Benzinga

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

2 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

2 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

3 months ago - By: Zacks Investment Research - Mentions: MNKD

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?

4 months ago - By: Zacks Investment Research - Mentions: BIIB CRMD

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26

4 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

4 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

4 months ago - By: Zacks Investment Research - Mentions: CPRX ACAD

Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?

5 months ago - By: Yahoo Finance

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy

5 months ago - By: Yahoo Finance

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target

5 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

6 months ago - By: Zacks Investment Research - Mentions: MRNA

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?

7 months ago - By: Zacks Investment Research - Mentions: SNY BIIB

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus

7 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

7 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

9 months ago - By: Benzinga

What Happened To Denali Therapeutics Stock Wednesday?

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

10 months ago - By: Denali Therapeutics Inc.

DENALI THERAPEUTICS INC (DNLI) Stock News

DNLI Latest News, Press Relases and Analysis

Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Denali Enters Into a $275M Funding Deal With Royalty Pharma

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Announces Board and Executive Leadership Updates

Denali Therapeutics Announces Board and Executive Leadership Updates

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

What Happened To Denali Therapeutics Stock Wednesday?

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights